RTP Mobile Logo
Breast Cancer Update, Issue 2, 2015
Released January 2016

Featuring interviews with Drs Beth Overmoyer, Sandra M Swain, Joyce O’Shaughnessy and Ruth M O’Regan. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Breast cancer (BC) continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Develop an evidence-based algorithm for the treatment of hormone-sensitive advanced BC, including the use of endocrine, chemotherapeutic and biologic agents.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing, recently approved and investigational targeted treatments.
    • Evaluate available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy.
    • Appraise novel treatment strategies under investigation in advanced BC (eg, anti-PD-1/PD-L1 antibodies, androgen receptor inhibitors).
    • Apply the results of current clinical data to the management of triple-negative BC.
    • Develop a plan of care for patients with advanced inflammatory BC, incorporating existing and novel treatment approaches.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr OvermoyerContracted Research: Genentech BioOncology, Incyte Corporation. Dr SwainAdvisory Committee: Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clinigen Group PLC, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Genentech BioOncology, Lilly, Merrimack Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Paid Travel: Genentech BioOncology. Dr O’ShaughnessyConsulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi, Takeda Oncology. Dr O’ReganAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Astellas Pharma Global Development Inc/Medivation Inc, AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Celgene Corporation, Eisai Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2016
    Expiration date: January 2017

Acknowledge and close

Listen to audio:
Breast Cancer Update, Issue 2, 2015
Released January 2016

Featuring interviews with Drs Beth Overmoyer, Sandra M Swain, Joyce O’Shaughnessy and Ruth M O’Regan. (Text and Audio Content)

Read print: